Xenetic Biosciences, Inc. (XBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on December 21, 2022, regarding Xenetic Biosciences, Inc., a Nevada corporation. The report details the conclusion of the Company's 2022 Annual Meeting of Stockholders, which was reconvened on this date to finalize voting on a specific proposal.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting results rather than financial performance.
Material Changes
The primary material change reported is the approval of an amendment to the Company's Articles of Incorporation. Stockholders voted to increase the authorized number of shares of common stock from 50,000,000 to 100,000,000 shares.
Voting Results and Management Commentary
Stockholders voted on Proposal Four at the reconvened Annual Meeting. The results were as follows:
- For: 7,204,486 votes
- Against: 1,131,034 votes
- Abstained: 110,245 votes
- Broker Non-Votes: None
The proposal was approved and adopted. No other matters were considered or voted upon at the meeting. The report contains no specific guidance, outlook, or discussion of risks beyond the standard filing requirements.
Investor Verification Checklist
- Verify the effective date of the Articles of Incorporation amendment with the State of Nevada.
- Confirm the current authorized share count in subsequent filings (e.g., 10-Q or 10-K).
- Review the Company's capitalization table to understand the impact of the increased authorized shares on potential future dilution.